Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004 on drug precursors (Text with EEA relevance)

Article 1	Scope and objectives
Article 2	Definitions
Article 3	Requirements for the placing on the market of scheduled
	substances
Article 4	Customer declaration
Article 5	Documentation
Article 6	Exemptions
Article 7	Labelling
Article 8	Notification of the competent authorities
Article 9	Guidelines
Article 10	Powers and obligations of competent authorities
Article 11	Cooperation between the Member States and the Commission
Article 12	Penalties
Article 13	Communications from Member States
Article 13a	European database on drug precursors
Article 13b	Data protection
Article 14	Implementing acts
Article 14a	Committee procedure
Article 15	Adaptation of Annexes
Article 15a	Exercise of the delegation
Article 16	Information about measures adopted by Member States
Article 17	Repeals

Article 18

- Entry into force Signature

ANNEX I

List of scheduled substances

ANNEX II

ANNEX III

- 1. Model declaration relating to individual transactions (category 1 or 2)...
- 2. Model declaration relating to multiple transactions (category 2)

- (1) OJ C 20 E, 28.1.2003, p. 160.
- (2) OJ C 95, 23.4.2003, p. 6.
- (3) Opinion of the European Parliament of 11 March 2003 (not yet published in the Official Journal), Council common position of 29 September 2003 (OJ C 277 E, 18.11.2003, p. 31) and position of the European Parliament of 16 December 2003 (not yet published in the Official Journal).
- (4) OJ L 326, 24.11.1990, p. 56.
- (5) OJ L 357, 20.12.1990, p. 1. Regulation as last amended by Commission Regulation (EC) No 1232/2002 (OJ L 180, 10.7.2002, p. 5).
- (6) OJ L 370 19.12.1992, p. 76. Directive as last amended by Regulation (EC) No 1882/2003 of the European Parliament and of the Council (OJ L 284, 31.10.2003, p. 1).
- (7) OJ L 184, 17.7.1999, p. 23.
- (8) Commission Directive 93/46/EEC of 22 June 1993 replacing and modifying the Annexes to Council Directive 92/109/EEC on the manufacture and placing on the market of certain substances used in the illicit manufacture of narcotic drugs and psychotropic substances (OJ L 159, 1.7.1993, p. 134).
- (9) Commission Directive 2001/8/EC of 8 February 2001 replacing Annex I to Council Directive 92/109/EEC on the manufacture and placing on the market of certain substances used in the illicit manufacture of narcotic drugs and psychotropic substances (OJ L 39, 9.2.2001, p. 31).
- (10) Commission Directive 2003/101/EC of 3 November 2003 amending Council Directive 92/109/EEC on the manufacture and placing on the market of certain substances used in the illicit manufacture of narcotic drugs and psychotropic substances (OJ L 286, 4.11.2003, p. 14).
- (11) Commission Regulation (EC) No 1485/96 of 26 July 1996 laying down detailed rules for the application of Council Directive 92/109/EEC, as regards customer declarations of specific use relating to certain substances used in the illicit manufacture of narcotic drugs and psychotropic substances (OJ L 188, 27.7.1996, p. 28). Regulation as amended by Regulation (EC) No 1533/2000 (OJ L 175, 14.7.2000, p. 75).
- (12) Commission Regulation (EC) No 1533/2000 of 13 July 2000 amending Regulation (EC) No 1485/96 laying down detailed rules for the application of Council Directive 92/109/EEC, as regards customer declarations of specific use relating to certain substances used in the illicit manufacture of narcotic drugs and psychotropic substances.

Changes to legislation:

There are outstanding changes not yet made to Regulation (EC) No 273/2004 of the European Parliament and of the Council. Any changes that have already been made to the legislation appear in the content and are referenced with annotations.

View outstanding changes

Changes and effects yet to be applied to :

- Annex 1 Table addition by EUR 2020/1737 Regulation (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
- Annex 2 Table addition by EUR 2020/1737 Regulation (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
- Art. 1 words substituted by S.I. 2019/742 reg. 13(2)
- Art. 3(2) words omitted by S.I. 2019/742 reg. 13(4)(a)
- Art. 3(6) words omitted by S.I. 2019/742 reg. 13(4)(b)
- Art. 3(7) omitted by S.I. 2019/742 reg. 13(4)(c)
- Art. 3(8) words substituted by S.I. 2019/742 reg. 13(4)(d)(i)
- Art. 4(1) words substituted by S.I. 2019/742 reg. 13(5)(a)
- Art. 4(3) words substituted by S.I. 2019/742 reg. 13(5)(b)
- Art. 4(4) substituted by S.I. 2019/742 reg. 13(5)(c)
- Art. 5(7) substituted by S.I. 2019/742 reg. 13(6)
- Art. 7 words substituted by S.I. 2019/742 reg. 13(7)
- Art. 8(3) substituted by S.I. 2019/742 reg. 13(8)
- Art. 9(1) words substituted by S.I. 2019/742 reg. 13(9)
- Art. 10 omitted by S.I. 2019/742 reg. 13(10)
- Art. 11 omitted by S.I. 2019/742 reg. 13(10)
- Art. 12 omitted by S.I. 2019/742 reg. 13(10)
- Art. 13 substituted by S.I. 2019/742 reg. 13(11)
- Art. 13a omitted by S.I. 2019/742 reg. 13(12)
- Art. 13b(1) omitted by S.I. 2019/742 reg. 13(13)(a)
- Art. 13b(2) words substituted by S.I. 2019/742 reg. 13(13)(b)
- Art. 13b(3)(4) omitted by S.I. 2019/742 reg. 13(13)(c)
- Art. 14 omitted by S.I. 2019/742 reg. 13(14)
- Art. 14a omitted by S.I. 2019/742 reg. 13(14)
- Art. 15 words substituted by S.I. 2019/742 reg. 13(15)
- Art. 15a substituted by S.I. 2019/742 reg. 13(16)
- Art. 16 omitted by S.I. 2019/742 reg. 13(17)

Changes and effects yet to be applied to the whole legislation item and associated provisions

- Signature words omitted by S.I. 2019/742 reg. 13(18)
- Art. 2(a) words substituted by S.I. 2019/742 reg. 13(3)(a)
- Art. 2(c) words substituted by S.I. 2019/742 reg. 13(3)(b)
- Art. 3(8)(c) omitted by S.I. 2019/742 reg. 13(4)(d)(ii)